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Cost effectiveness of primary care referral to a commercial
provider for weight loss treatment, relative to standard care:
a modelled lifetime analysis
NR Fuller1, H Carter2, D Schofield2, H Hauner3, SA Jebb4, S Colagiuri1 and ID Caterson1
BACKGROUND: Because of the high prevalence of overweight and obesity, there is a need to identify cost-effective approaches for
weight loss in primary care and community settings.
OBJECTIVE: To evaluate the long-term cost effectiveness of a commercial weight loss programme (Weight Watchers) (CP)
compared with standard care (SC), as deﬁned by national guidelines.
METHODS: A Markov model was developed to calculate the incremental cost-effectiveness ratio (ICER), expressed as the cost per
quality-adjusted life year (QALY) over the lifetime. The probabilities and quality-of-life utilities of outcomes were extrapolated from
trial data using estimates from the published literature. A health sector perspective was adopted.
RESULTS: Over a patient’s lifetime, the CP resulted in an incremental cost saving of AUD 70 per patient, and an incremental 0.03
QALYs gained per patient. As such, the CP was found to be the dominant treatment, being more effective and less costly than SC
(95% conﬁdence interval: dominant to 6225 per QALY). Despite the CP delaying the onset of diabetes byB10 months, there was
no signiﬁcant difference in the incidence of type 2 diabetes, with the CP achieving o0.1% fewer cases than SC over the lifetime.
CONCLUSION: The modelled results suggest that referral to community-based interventions may provide a highly cost-effective
approach for those at high risk of weight-related comorbidities.
International Journal of Obesity (2014) 38, 1104–1109; doi:10.1038/ijo.2013.227
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INTRODUCTION
The prevalence of overweight and obesity is placing a substantial
burden on health-care resources, particularly in developed
countries.1 Because of limited health-care budgets, policy
makers are seeking evidence of the cost effectiveness of
interventions before publicly subsidising programmes. It is
therefore imperative that obesity management programmes that
are both efﬁcacious and cost effective are identiﬁed and
implemented.
A partnership between primary care providers and commercial
organisations presents a practical approach for a population-
based weight loss programme, whereby participants can beneﬁt
from early lifestyle intervention for weight management. Our
recent randomised controlled trial (RCT) involving three countries
(Australia, United Kingdom and Germany) showed that referral to
a commercial weight loss community intervention programme
(Weight Watchers) (CP) produced greater weight loss over 1 year
than standard care (SC).2 These results conﬁrmed observational
data3,4 that a shared care approach between primary care
providers and commercial organisations has the potential to
deliver weight management programmes scalable to a national
level in a community setting.
Importantly, this shared care approach was shown to be cost
effective based on a prospectively designed within-trial analysis.5
The key strengths of the within-trial cost-effectiveness analysis
were the certainty of the results as they were based directly on
observed trial cost and efﬁcacy data. The limitations were the
short time horizon for analysis (1 year), the assumption that all
weight loss was maintained, and that several cost offsets including
reduced rates of obesity-related disease were not captured.5
Collection of follow-up data at 2 years has since been performed6
that enables us to report on weight regain statistics after cessation
of the weight loss intervention.
Previous estimates of the cost of the CP have been reported,
but were based on small studies with limited data.7 The aim of this
study was to develop a decision analytic model to estimate the
long-term effectiveness and cost effectiveness of the CP
compared with SC in reducing rates of obesity and obesity-
related disease in a population of overweight and obese adults.
The model builds on our within-trial cost-effectiveness analysis5 by
extrapolating costs and outcomes from the 2-year RCT6 to the
lifetime of the trial population.
MATERIALS AND METHODS
A decision model was developed to estimate the lifetime costs and health
outcomes of the CP compared with SC in a simulated cohort of overweight
and obese patients. The baseline characteristics of the modelled cohort
and the weight loss results for the initial 2 years of the model were
imputed directly from data collected in the RCT.2,6
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The net effectiveness of each strategy was quantiﬁed in terms of quality-
adjusted life years (QALYs). This involved weighting the time spent in each
health state by the health-related quality-of-life value (utility) associated
with that state (where 0¼ death and 1¼ full health). Incremental cost
effectiveness was measured in terms of the cost per QALY gained. A health
sector perspective was adopted and an annual discount rate of 3.5% was
applied to all future costs and health outcomes.
Randomised controlled trial
A multicentre RCT was undertaken whereby overweight and obese adults
were recruited by their general practitioners (GPs) and randomised to
receive 1 year of access to either the CP or SC by a primary care provider in
Australia, United Kingdom and Germany.2 Participants randomised to the
CP group received vouchers to attend a weekly community CP meeting
(Weight Watchers). Those randomised to SC received weight loss advice
delivered by a GP/primary care professional at their local medical practice.
The frequency of SC visits was at the discretion of the GP and the
participant. All participants were aged X18 years with a body mass index
(BMI) of 27–35 kgm 2, and had at least one risk factor for obesity-related
disease. Risk factors included central adiposity (waist circumference
488 cm in women and4102 cm in men); type 2 diabetes without insulin
treatment; family history of type 2 diabetes; previous gestational diabetes;
impaired glucose tolerance or impaired fasting glycaemia; mild-to-
moderate dyslipidemia (deﬁned by national guidelines), or treatment for
dyslipidemia; treatment for hypertension; polycystic ovarian syndrome or
infertility without apparent cause other than weight; lower-limb osteoar-
thritis; or abdominal hernia. A full list of inclusion and exclusion criteria, as
well as a more in-depth description of the two intervention groups, are
reported with the primary ﬁndings from the study.2 After the 1-year
intervention, participants were then followed-up at 18 and 24 months,
during which time they could self-select their method of weight
management, or do nothing.6
Model structure
The Markov process deﬁnes a set of discrete health states associated with
overweight and obesity, and a set of probabilities that govern the
likelihood of transitioning from one state to another at the end of each
1-year cycle (see Figure 1).8 Each health state was assigned an estimate of
the cost required to provide typical health care over the cycle and a utility
weighting that reﬂected the QALYs gained per cycle (deﬁned under
‘Resource Use and Costs’). A half-cycle correction was used in the Markov
process. The model was constructed using TreeAge Pro Suite 2008
(Williamstown, MA, USA) with links to Excel.
Transition probabilities and health state utilities
All transition probabilities and health state utilities are listed in Table 1.
Consistent with the baseline data collected in the RCT, patients entering
the model had an average age of 47 years2 and were assigned to begin the
model in either an overweight, obese or type 2 diabetes health state. All
patients remained in the model until death or until they reached the age of
99 years.
Trial data were used to assign the probabilities of transitioning
between health states at the end of the intervention period (1 year),
and at the end of follow-up (2 years). Based on the 2-year follow-up trial
data at 1 year post completion of the interventions, patients experienced
an average weight regain equivalent to 0.09 BMI points per month for
the CP group and 0.03 BMI points per month for the SC group.
As the entry criterion for the study was a BMI of 27–35 kgm 2, those
with a BMI of o27 kgm 2 (o26.55 kgm 2) at the end of the
intervention and at the end of follow-up were considered to be in a
normal BMI range.
Based on a meta-regression performed by Dansinger et al.9 (whereby at
5.5 years post intervention, no residual weight loss remained) it was
assumed that participants in both groups had a weight regain of 0.03 BMI
points per month after the end of the 2-year follow-up. In our study, this
was equivalent to B1 kg per year. When applied from the conclusion of
the trial follow-up, this assumption resulted in participants in the CP group
being projected to regain all their weight loss by B5 years post
intervention as compared with 4 years post intervention for participants
in the SC group. It was assumed for both groups that no residual weight
loss remained indeﬁnitely.
Comparing our methodology used with other literature, this was seen to
be a conservative weight regain approach post 2-year follow-up. Ara
et al.10 reported an increase in BMI of 0.175 per year for women for an
equivalent nondiabetic cohort, which is less than the increase in BMI that
we modelled (0.36 BMI units per year). Furthermore, as shown by the
results from the 10-year Diabetes Prevention Program (DPP) Outcomes
Study,11 weight regain is shown to slow down over time (after 2 years) for a
similar cohort of patients. Data from the DPP shows that a 2-kg weight loss
is maintained up to 10 years;11 however, this was not assumed for our
study.
The probabilities of developing type 2 diabetes for those with normal,
overweight and obese BMI ranges were sourced from the 2005 AusDiab
Report.12 Age-speciﬁc annual mortality rates for patients with and without
type 2 diabetes were sourced from Magliano et al.14 (also reported by
Keating et al.13) that combined data from the AusDiab study with national
Australian mortality data.
Utility values for each health state in the Markov model were based on
patient responses to the IWQOL-Lite (Impact of Weight on Quality of Life
Questionnaire-Lite)15,16 that was collected as part of our trial on ﬁve
occasions over 2 years (baseline, months 6, 12, 18 and 24). A utility score
was derived from the patient responses to the questionnaire using the
algorithm described by Brazier et al.17
Resource use and costs
All resource use and costs are listed in Table 2. Programme costs
associated with the CP group were based on the market price of attending
the programme and were sourced directly from Weight Watchers Australia
(www.weightwatchers.com.au). This consisted of a monthly payment plan
and included unlimited access to meetings and online electronic web
tools. The cost of the referral visit to the CP was also included in the
costing. For the SC group, the cost applied was that of a consultation
lasting p20min with a GP. There were no programme costs assigned for
either group during the follow-up period (beyond 1 year) as the choice of
weight loss method, if any, was not recorded.
The mean annual health-care costs for patients living with type 2
diabetes were sourced from the Australian Diabetes, Obesity and Lifestyle
Study.18 Average medication costs for those in each BMI range (healthy,
overweight and obese) were from a study by Colagiuri et al.19
All costs were measured in Australian dollars (AUD). Costs sourced from
alternative years were presented in 2010–2011 values by applying the
relevant price inﬂators or deﬂators.20
Uncertainty analysis
A probabilistic sensitivity analysis was undertaken to examine the effect of
multiparameter uncertainty around estimates of costs, utilities and
probabilities. A Monte Carlo simulation of the patient cohort with 10 000
iterations was used to estimate the 95% uncertainty interval around the
mean incremental cost-effectiveness ratio (ICER) as well as probabilities of
acceptable cost-effectiveness thresholds.
Scenario analysis
The cost-effectiveness analysis was based on commercial pricing decisions

















Figure 1. Health states included in the Markov model following a CP
versus SC care for weight loss treatment.
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market prices is considered the most practical approach in costing
analyses.8 A scenario analysis was performed to examine the cost-
effectiveness impacts of reducing programme costs in Australia to the
equivalent of those from the UK National Health Service (NHS) Weight
Watchers referral scheme (GBP 45 for 12 sessions4). As the CP is identical
across countries and the cost to deliver the intervention similar, we
assumed that this cost would represent the likely Australian government
cost of publicly subsidising the programme. The total cost applied was
based on an attendance of 36 CP sessions over 12 months (GBP 135–12
session cost multiplied by 3). The Weight Watchers NHS referral scheme
was used as it is a system currently in place.
Sensitivity analysis
A sensitivity analysis was performed to estimate the cost effectiveness of
the CP when including the costs associated with patient travel to attend
either CP or SC consultations. The number of participant visits to
their primary care provider for weight loss advice (SC group), or to the
Table 1. Annualised parameter estimates used in Markov model





Probability of developing diabetes for normal health state 0.004 (0.002) 0.004 (0.002) AusDiab Report
2005 (ref.12)
Probability of developing diabetes for overweight health state 0.008 (0.003) 0.008 (0.003) AusDiab Report
2005 (ref.12)
Probability of developing diabetes for obese health state 0.016 (0.004) 0.016 (0.004) AusDiab Report
2005 (ref.12)
Mortality rate for those with type 2 diabetes (age 47–99 years) 0.008–0.328 0.008–0.328 Magliano et al.14
Keating et al.13
Mortality rate for those without type 2 diabetes (age 47–99 years) 0.002–0.332 0.002–0.332 Magliano et al.14
Keating et al.13
Probability of healthy BMI range (start of trial) 0 0 RCT
Probability of overweight BMI range (start of trial) 0.331 0.331 RCT
Probability of obese BMI range (start of trial) 0.603 0.603 RCT
Probability of type 2 diabetes (start of trial) 0.066 0.066 RCT
Probability of obese BMI range at start of trial to overweight BMI range at 12 months 0.201 (0.375) 0.439 (0.305) RCT
Probability of overweight BMI range at start of trial to healthy BMI range at 12 months 0.188 (0.639) 0.414 (0.398) RCT
Probability of healthy BMI range at 12 months to overweight BMI range at 24 months 0.320 (0.680) 0.509 (0.346) RCT
Probability of overweight BMI range at 12 months to obese BMI range at 24 months 0.099 (0.889) 0.286 (0.571) RCT
Probability of diabetes remission at 12 months 0.074 0.167 RCT
Quality-of-life adjustments
Normal health state 0.81 (0.07) 0.81 (0.07) RCT
Overweight health state 0.81 (0.06) 0.81 (0.06) RCT
Obese health state 0.78 (0.07) 0.78 (0.07) RCT
Type 2 diabetes 0.75 (0.10) 0.75 (0.10) RCT
Start age 47.4 47.4 RCT2
Abbreviations: BMI, body mass index; RCT, randomised controlled trial. Values are presented as mean (standard deviation); standard deviation as tested in the
probabilistic sensitivity analysis.
Table 2. Cost inputs for Markov model
Resource Unit cost (AUD) Average number of visits





WW attendance $59.95 per month 33.0 $719.40 www.weightwatchers.com.au
Primary care referral $34.90 per participant 1.0 $34.90 MBS,31 item 23
Patient travelb $12.60 per round trip 33.0 $415.80 ATO32
Standard care
General practitioner (GP) consult $34.90 10.7 $373.43 MBS,31 item 23
Patient travelb $12.60 per round trip 10.7 $134.82 ATO32
Health-care costs
Normal health statec $1749 (5667) 1 $1749 (5667) Colagiuri et al.19
Overweight health statec $2159 (5885) 1 $2159 (5885) Colagiuri et al.19
Obese health statec $2598 (5654) 1 $2598 (5509) Colagiuri et al.19
Type 2 diabetes health statec $4491 (5669) 1 $4491 (5669) Australian Diabetes, Obesity and
Lifestyle Study18
Abbreviations: ATO, Australian Taxation Office; AUD, Australian dollar; MBS, Medicare Benefits Schedule; WW, Weight Watchers. aThe CP and SC costs only
apply to the 12-month intervention period. There were no programme costs during the 24-month follow-up period. bThis cost was only included in the
sensitivity analysis. cCosts are reported as mean (standard deviation).
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CP (CP group), was recorded throughout the 1-year study. Those attending
the CP had B3 times more visits over the 1-year treatment period than
those receiving SC (Table 2). Patients were assumed to have travelled
within a 10-km radius to either their local CP or primary care clinic.
Opportunity costs of employment were not considered because partici-
pants could attend their intervention outside working hours, during their
lunch break or on weekends. Childcare costs were not considered as
children of any age are welcome at the CP meetings and can accompany
their parent to a SC visit.
RESULTS
Modelled results
Using base case assumptions, the CP resulted in an additional 50
life years gained per 1000 patients treated, and an additional 50
years spent in a normal BMI range per 1000 patients (Table 3). The
average onset of type 2 diabetes in the CP group was delayed by
10.29 months (0.85 years) when compared with patients in SC.
However, there was no statistically signiﬁcant difference (o0.1%)
in the probability of developing type 2 diabetes over the
remainder of the patient’s lifetime (34.95% and 34.99% for the
CP and SC groups, respectively).
After discounting costs and beneﬁts by 3.5%, the CP
cost an additional AUD 123 over the ﬁrst 5 years post
treatment. This produced an ICER of AUD 11 260 per QALY.
Over a patient’s lifetime, the CP resulted in an incremental cost
saving of AUD 70 per patient, and an incremental 0.03 QALYs
gained per patient. As such, the CP was found to be the
dominant treatment, being more effective and less costly than
SC. The 95% conﬁdence interval ranged from dominant to 6225
per QALY.
Probabilistic sensitivity analysis
The results of the Monte Carlo analysis for the cost effectiveness
of the CP relative to SC are presented on a cost-effectiveness
plane in Figure 2. Based on this analysis, the probability of the
CP being a cost-effective treatment at an ICER of AUD 50 000
was 77.9%.
Scenario analysis
When the programme costs of the CP in Australia were reduced to
the equivalent of the Weight Watchers NHS referral scheme, our
base case results were strengthened and the CP remained the
dominant intervention.
Sensitivity analysis
When including the costs associated with patient travel in our
analysis, programme costs increased to AUD 1170 and AUD 508
for the CP and SC groups, respectively. This resulted in an ICER of
AUD 6389 per QALY (95% uncertainty interval: CP dominant to
10 925 per QALY) for the CP relative to SC.
DISCUSSION
Although the CP was associated with a higher initial cost than SC,
these extra costs were offset by the longer-term health beneﬁts
associated with an increased rate of weight loss (and therefore
lower health-care resource use) when patients were followed over
Table 3. Markov model results (5-year and lifetime means per patient)
After 5 years (age o53 years) Lifetime (age¼ 99 years)
CP SC CP SC
Cumulative incidences
Total life years 6.94 6.94 34.64 34.59
Years spent in normal health state 0.28 0.16 0.49 0.44
Years spent in overweight health state 2.51 2.29 10.24 9.66
Years spent in obese health state 3.50 3.80 16.22 16.55
Developing type 2 diabetes 7.77% 8.02% 34.95% 34.99%
Mortality rate for those with type 2 diabetes 0.49% 0.53% 39.59% 40.34%
Cost effectiveness analysis
QALYs discounted 4.87 4.86 15.31 15.28
Cost discounted AUD 16 667 AUD 16 544 AUD 55 511 AUD 55 581
Incremental efficacy CP¼ 0.01 QALYs CP¼ 0.03 QALYs
C/E AUD 3422 AUD 3405 AUD 3625 AUD 3638
ICER CP¼AUD 11 260 per QALY CP dominant
QALYs undiscounted 5.48 5.46 27.11 27.04
Cost discounted AUD 18 676 AUD 18 586 AUD 100 379 AUD 100 626
Incremental efficacy CP¼ 0.01 QALYs CP¼ 0.07 QALYs
C/E AUD 3410 AUD 3401 AUD 3703 AUD 3721
ICER CP¼AUD 7349 per QALY CP dominant
Abbreviations: AUD, Australian dollar; BMI, body mass index; C/E, cost effectiveness; CP, commercial programme; ICER, incremental cost effectiveness ratio;
QALY, quality-adjusted life year; SC, standard care.
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Incremental Effectiveness (quality adjusted life years)
Figure 2. Incremental cost-effectiveness scatterplot of the commercial
weight loss programme vs standard care.
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the lifetime. The CP was therefore a dominant intervention (that is,
both more effective and less costly than SC). The lifetime analysis
presented here extrapolates from the results of the within-trial
cost-effectiveness analysis conducted alongside the RCT, where an
ICER of AUD 18 085 per QALY was reported.5
When the commercial price of the CP was re-evaluated in
accordance with the likely costs of the programme if it were to be
funded through the health system, the base case result was
strengthened and the CP remained the dominant option. The
costs of patient travel were estimated in a separate sensitivity
analysis as those attending the CP had more frequent visits than
those receiving SC (B3 times more visits over 1 year), which may
have had a large contribution to the success of the CP. When
these costs were included in the analysis, the CP became more
expensive than SC, but remained highly cost effective with an ICER
of AUD 6389 that was well below the commonly accepted
threshold of $50 000 per QALY.21–23 It may be argued that patient
time to attend the CP or GP consultations should also be included;
however, a large beneﬁt of these services is that they are available
at lunchtimes, after work hours and on weekends, thereby
minimising the opportunity costs of paid employment.
When GPs are given adequate support services such as those in
the SC arm of our study, as well as the Counterweight Programme
in the United Kingdom,24 they (GPs) have been found to achieve a
weight loss of 3 kg at 1 year. Although this approach is cost
effective when compared with background rates of population
weight gain,25 our results indicated that the CP provided a
relatively more effective and less costly long-term approach.
Despite the higher initial programme costs associated with the CP,
and no signiﬁcant difference in overall incidence of type 2
diabetes between groups (o0.1%), the quality-of-life beneﬁts and
lower levels of resource use associated with patients being in a
healthier BMI range resulted in the CP being cost saving over the
lifetime. Importantly, this shared care approach has the potential
to be delivered on a large scale and in community settings. This
suggests that we should be using the CP as a cost-effective means
for community weight control and it is a suitable support resource
for GPs to refer patients to. However, the CP may be beyond the
ﬁnancial reach of a substantial portion of the population,
particularly those who need it most.26
Although other studies have reported on the cost effectiveness
of the CP, these were small in scale and reliant on several
assumptions.7 However, cost-effectiveness ratios for other adult
weight loss interventions that incorporated dietary and exercise
counselling have been published. The DASH and low-fat diet
programmes (as reported by Forster et al.27) were found to have
incremental cost-effectiveness ratios of AUD 12 000 and AUD
13 000 per disability-adjusted life year, respectively, when patient
time and travel were not included.27 An economic evaluation of
weight loss interventions in overweight and obese women found
the most cost-effective option to be a diet, exercise and
behavioural modiﬁcation programme at a cost of USD 12 600
per QALY.28 Although there are challenges in comparing with
previous cost-effectiveness analyses for reducing overweight and
obesity in an adult population (including differences in costing
perspectives, timeframe for outcomes measured, modelling
methods, discounting rates and assumptions around the
sustainability of intervention effects), the CP, being a cost saving
intervention, is highly favourable when compared with other diet
and exercise interventions.
Previous studies have found surgically induced weight loss to
be a cost-effective approach for managing obesity and remission
of type 2 diabetes.13,29,30 Compared with nonsurgical
management of obesity, this was found to produce an ICER of
GBP 11 000 per QALY,30 with a more recent systematic review
conﬁrming these results.29 However, the majority of ICERs
reported for bariatric surgery are higher than those for other
obesity management approaches. In this context, it would be a
better use of government resources to support approaches, such
as those reported here, that are low-cost programmes that help
promote weight loss and delay the onset of type 2 diabetes.
The strength of the methodology applied in this study lies in its
ability to synthesise trial evidence of efﬁcacy, resource use and
patient preferences associated with weight loss interventions in
an explicit and transparent manner. This modelling approach
allows us to extrapolate 2-year follow-up results from a robust
community intervention to project the outcomes for patients over
a lifetime. The estimates of the cost effectiveness are robust. This
is unsurprising as minimal assumptions were required within the
model and all the transition probabilities applied were based on
the highest levels of evidence (RCTs and meta-analyses).
A limitation of our study was that only one clinical outcome
(type 2 diabetes) was assessed. We chose to model the impacts on
this condition alone as it was the only condition for which we had
baseline prevalence rates, and because the link between BMI and
type 2 diabetes has been well established. Exclusion of other
obesity-related diseases where the evidence of the association
with BMI is scarcer would have required more assumptions and
hence have produced greater uncertainty in the cost-effectiveness
estimates. However, if additional obesity-related diseases were to
be included in the model, it is likely that our existing conclusions
would be strengthened further.
CONCLUSION
The CP was found to be a more effective and less costly
intervention than SC in overweight and obese individuals. It also
delayed the onset of type 2 diabetes. This suggests that a greater
emphasis on referral to commercial weight loss programmes may
provide a highly cost-effective approach for those at high risk of
weight-related comorbidities.
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